Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...

BlackfinBio Limited has received approval from the FDA to trial a novel therapy for Hereditary Spastic Paraplegia ...

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

By embracing a mix of co-innovation and best practices, stakeholders can boost productivity, streamline clinical trials, and ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

The U.S. Food and Drug Administration (FDA) recently announced it plans to phase out animal testing in the development of monoclonal ...

With the clinical hold on the tab-cel application lifted, phase 2 and 3 trials of the T-cell immunotherapy in patients with ...

The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

In April 2025, Novartis Pharmaceuticals announced study is to establish the efficacy, safety, and tolerability of ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Researchers have discovered a promising new drug combination that significantly lowers “bad” LDL cholesterol for people whose ...

In April 2025, Incyte Corporation announced a study will be conducted to compare the efficacy of axatilimab versus placebo in ...